BNET Industries
Market Cap:$8.6M
Last Fiscal Year Sales:$14.7M
- Public
- US
Dow Jones Description
Neurobiological Technologies, Inc. is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug with multiple mechanisms of action that is specifically designed to double the time period that patients can be treated after the onset of a stroke. NTI also has the right to receive royalty payments from sales of Namenda(R) (memantine HCL), an approved drug marketed for Alzheimer's disease, and the right to receive payments from the development and marketing of XERECEPT(R) (corticorelin acetate injection), an investigational drug in Phase 3 clinical development for swelling associated with brain tumors. Additionally, NTI has rights to two compounds in early-stage development for Alzheimer's and Huntington's diseases.
President & CEO
Paul E. FreimanNumber of Employees 32
Contact Information
2000 Powell Street
Suite 800
Emeryville, California 94608
(510) 595-6000
Peer Companies
NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414
Recent Events
-
Neurobiological Technologies, Inc. NTII Announces Extraordinary Dividend of $0.18 per Share Company also Announces Timing...
-
Neurobiological Technologies liquidation gets stockholders OK
-
Neurobiological Technologies' Stockholders Approve Plan Of Liquidation And Dissolution - Quick Facts
-
UPDATE 1-Neurobiological board approves liquidation plan
News & Analysis
Filter by
neurobiological technologies inc. - All News and Analysis
Neurobiological Tech Provides an Exit Opportunity
Greenbackd submits: Neurobiological Technologies Inc NTII has filed its 10Q for the period ended March 31, 2009. After reviewing the 10Q, we have reduced our estimate of NTII’s liquidation value to $19.6M or $0.73 per share. NTII closed on Friday at $0.72, which is approximately our estimate of its...
NTII on the Block - and Trading at Discount
Greenbackd submits: Neurobiological Technologies Inc (Nasdaq: NTII) has engaged a financial adviser to explore a sale of the company or its major assets to determine “if there is a transaction more beneficial to our shareholders than a liquidation,” according to its CEO, William Fletcher. We’ve been following...
Neurobiological Technologies, Inc. Review in Progress.
M2 PRESSWIRE-3 March 2008-The SI Report: Neurobiological Technologies, Inc. Review in ProgressC1994-2008 M2 COMMUNICATIONS LTD RDATE:03032008 Streetinvesting.com has now resumed our progressive review of Neurobiological Technologies, Inc. (Nasdaq: NTII) after it traded up 2% Monday, early in the morning...
Neurobiological Technologies F2Q07 (Qtr End 1/31/07) Earnings Call Transcript
Question-and-Answer SessionOperator Absolutely sir. The question and Answer session today will be conducted electronically. If you would like to ask a question, please do so by pressing the star key followed by the digit one on your touch tone telephone. If you are using a speaker phone, please...
Biogen, Elan to seek FDA OK on Tysabri and Neurobiological Technologies, Inc. announces sale of XERECEPT.
M2 PRESSWIRE-21 September 2005-US Financial Network: Biogen, Elan to seek FDA OK on Tysabri and Neurobiological Technologies, Inc. announces sale of XERECEPTC1994-2005 M2 COMMUNICATIONS LTD RDATE:21092005 City of Industry, CA - Biotechnology industry news provided by Financial News USA (OTC: FNWU)...
OTCNetStocks.com announces the inclusion of Neurobiological Technologies Inc. to its Focus 30 Model Portfolio.
M2 PRESSWIRE-28 November 2000-OTCNetStocks.com: OTCNetStocks.com announces the inclusion of Neurobiological Technologies Inc. to its Focus 30 Model Portfolio C1994-2000 M2 COMMUNICATIONS LTD RDATE:28112000 Orlando, FL -- OTCNetStocks.com, an online publication of Stock News Media Corp. announced that Neurobiological...
Neurobiological Technologies Inc. announces public offering of common stock
Neurobiological Technologies Inc. (NASDAQ:NTII) announced that it commenced today a public offering of 2,200,000 shares of its common stock at a price of $3.25 per share.All of the shares were sold by the Company. The Company has granted the underwriters an option to purchase an additional 330,000 shares to...
Neurobiological Technologies Inc. Files Post-Effective Amendment to Registration Statement
RICHMOND, Calif.--BUSINESS WIRE--Feb. 8, 1996--Neurobiological Technologies Inc. (Nasdaq symbol: NTII) announced today that it has filed a post-effective amendment to its registration statement on Form SB-2 relating to an offering of 2,000,000 shares of the Company's common stock.The Company previously postponed the offering because two executive officers purchased a total...
Neurobiological Technologies Inc. announces public offering of common stock
RICHMOND, Calif.--BUSINESS WIRE--Jan. 30, 1996-- Neurobiological Technologies Inc. (NASDAQ:NTII) announced that it commenced today its public offering of 2,400,000 shares of its common stock at a price of $3.50 per share.All of the shares were sold by the company. The company has granted the underwriters an option to purchase...
Neurobiological Technologies, Inc. Announces Proposed Public Offering Of Common Stock
RICHMOND, Calif.--BUSINESS WIRE--Dec. 6, 1995--Neurobiological Technologies, Inc. (Nasdaq symbol: NTII) announced today that it has filed with the Securities and Exchange Commission a registration statement relating to the proposed public offering of 2,000,000 shares of its Common Stock. All of the shares are to be sold by the company.The...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Paul E. Freiman | President & CEO |
| Matthew Loar | Vice President and Chief Financial Officer |
| Warren W. Wasiewski | Vice President, Chief Medical Officer |
| David E. Levy | Vice President, Clinical Development |
| Karl G. Trass | Vice President, Regulatory Affairs & Quality Assurance |
| Stephen J. Petti | Vice President |
| David C. Chou | Director, Chemistry, Nfg & Controls |
| Stephen C. Ferruolo | Secretary |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Abraham E. Cohen | Chairman |
| Abraham Sofaer | Board of Directors |
| Enoch Callaway | Board of Directors |
| F. Van Kasper | Board of Directors |
| John B. Stuppin | Board of Directors |
| Theodore L. Eliot | Board of Directors |
| William A. Fletcher | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Syntex Corporation | Chief Executive Officer | Current |
| Neurobiological Technologies, Inc. | President & CEO | Current |
| Scigen Ltd | Leading Independant Director | Current |
| Penwest Pharmaceuticals, Co. | Chairman | Current |
| Omware, Inc. | Director | Current |
| Phytos Inc | Director | Current |
| NovaBay Pharmaceuticals, Inc. | Board of Directors | Current |
| Scigen Ltd | Board of Directors | Current |
| NeoPharm, Inc. | Board of Directors | Current |
| Novacal Pharmaceuticals, Inc. | Board of Directors | Current |
| Calypte Biomedical Corporation | Board of Directors | Current |
| Neurobiological Technologies, Inc. | Board of Directors | Current |
| Syntex Corporation | chairman | Former |
| Penwest Pharmaceuticals, Co. | Board of Directors | Former |
| Calypte Biomedical Corporation | Director | Former |
| Nti, Inc. | Director | Former |
| Fordham University | B.S. Degree In Pharmacy | Former |
| Organization | Position | Status |
|---|---|---|
| Osteologix, Inc. | Chief Financial Officer | Current |
| Neurobiological Technologies, Inc. | Vice President and Chief Financial Officer | Current |
| Genelabs Technologies, Inc. | CFO | Former |
| PricewaterhouseCoopers | Former | |
| University of California, Berkeley | B.A. in Legal Studies | Former |
| Organization | Position | Status |
|---|---|---|
| Neurobiological Technologies, Inc. | Vice President, Chief Medical Officer | Current |
| American Heart Association, Inc. | Current | |
| Pediatric Neurology Associates | Consultant | Former |
| Lancaster General Hospital | Chairman | Former |
| The State University of New York | Doctorate of Medicine | Former |
| The State University of New York | Masters of Science In Biochemistry | Former |
| Rutgers College | Bachelor of Arts In Biology Cum Laude | Former |
| Organization | Position | Status |
|---|---|---|
| Neurobiological Technologies, Inc. | Vice President, Clinical Development | Current |
| DOV Pharmaceutical, Inc. | senior director | Former |
| Harvard Medical School | doctor of medicine degree | Former |
| Harvard College | B.A. in chemistry and physics | Former |
| Organization | Position | Status |
|---|---|---|
| Neurobiological Technologies, Inc. | Vice President, Regulatory Affairs & Quality Assurance | Current |
| Genentech, Inc. | Senior Manager for Regulatory Affairs | Former |
| Indiana University | bachelor's degree in chemistry | Former |
| Organization | Position | Status |
|---|---|---|
| Neurobiological Technologies, Inc. | Vice President | Current |
| Nti, Inc. | Vice President of Product Development | Former |
| Dominican College | B.S.N. degree in nursing education | Former |
| Organization | Position | Status |
|---|---|---|
| Neurobiological Technologies, Inc. | Director, Chemistry, Nfg & Controls | Current |
| Organization | Position | Status |
|---|---|---|
| Neurobiological Technologies, Inc. | Secretary | Current |
Abraham E. Cohen has been a director of NTI since March 1993 and has been chairman of the board since August 1993. From 1982 to 1992, Mr. Cohen served as Senior Vice President of Merck & Co. and from 1977 to 1988 as President of the Merck Sharp & Dohme International Division ("MSDI"). While at Merck, he played a key role in the development of Merck's international business, initially in Asia, then in Europe and, subsequently, as President of MSDI, which manufactures and markets human health products outside the United States. Since his retirement from Merck and MSDI in January 1992, Mr. Cohen has been active as an international business consultant. He was a director of Agouron Pharmaceuticals, Inc. until its merger with Warner-Lambert Company. He is currently Chairman and President of Kramex Corporation and serves as a director of four other public companies: Akzo Nobel N.V., Chugai Pharmaceutical Co., Teva Pharmaceutical Industries, Ltd. and Vasomedical, Inc.
| Organization | Position | Status |
|---|---|---|
| Neurobiological Technologies, Inc. | Chairman | Current |
| Neurobiological Technologies, Inc. | Chairman | Current |
| Merck & Co. Inc. | Senior Vice President | Former |
| Agouron Pharmaceuticals, Inc. | Director | Former |
| Nti, Inc. | Director | Former |
| Organization | Position | Status |
|---|---|---|
| Plc Diagnostics | Founder & Chairman of The Board | Current |
| Neurobiological Technologies, Inc. | Board of Directors | Current |
| Mlt Research Limited | Director | Current |
| Nti, Inc. | Director | Current |
| Gen-Probe Inc. | Board of Directors | Current |
| Plc Diagnostics | Board of Directors | Current |
| Columbia University Law School | Professor | Former |
| United States Department of State | Senior Legal Adviser | Former |
| American Arbitration Association | qualified arbitrator | Former |
| New York University | L.L.B. degree | Former |
| New York University School of Law | L.L.B. | Former |
| Yeshiva University | B.A. In History | Former |
Is a founder of the Company and served as a director of the Company from September 1987 to February 2008. Dr. Callaway previously served as chairman of the Board of the Company from September 1987 to November 1990, as co-chairman of the Board of the Company from November 1990 until August 1993, as Vice President of the Company from September 1988 until August 1993 and as Secretary of the Company from September 1988 until September 1991. Dr. Callaway has been Emeritus Professor of Psychiatry at the University of California, San Francisco since 1986, where he also served as Director of Research at the Langley Porter Psychiatric Institute from 1959 to 1986. Dr. Callaway was Staff Psychiatrist, SFVAMC, 1996-1997. He is a member of the Institutional Review Board for SAM Technologies, Inc and Abratech, Inc. He continues to practice clinical psychopharmacology part time.
| Organization | Position | Status |
|---|---|---|
| Neurobiological Technologies, Inc. | Board of Directors | Current |
| Nti, Inc. | founder | Former |
| Columbia University | M.D. | Former |
F. Van Kasper joined the NTI board of directors in January 2004 and serves as chairman of the company's audit committee. Prior to his retirement in March 2003, Mr. Kasper served as Chairman of Wells Fargo Securities, the institutional brokerage and investment bank for Wells Fargo and Company. Mr. Kasper entered the brokerage business in 1964 with Merrill Lynch and in 1978 co-founded Van Kasper and Company, a regional investment bank. As Chairman and CEO of Van Kasper, he guided its growth from a handful of employees to one with over 350 employees in 15 offices in 4 states when the firm was sold in 1999. During his investment career, Mr. Kasper was elected as a Governor of the National Association of Securities Dealers (NASD) and as a Director and Vice Chairman of the Securities Industry Association (SIA). Mr. Kasper is active in the Bay Area non-profit community, most recently as Chairman of the Investment Committee for the University of California San Francisco Foundation (UCSF) and serves as Chairman Emeritus for San Francisco's Exploratorium Museum.
| Organization | Position | Status |
|---|---|---|
| Neurobiological Technologies, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Fiberstars, Inc. | chairman | Current |
| Fiberstars, Inc. | Board of Directors | Current |
| Neurobiological Technologies, Inc. | Board of Directors | Current |
| Nti, Inc. | founder | Former |
Theodore L. Eliot, Jr. has served as a director of NTI since August 1992. He joined the company in 1988 as Vice President. Mr. Eliot retired from the United States Department of State in 1978, after a 30-year career in which he held senior posts in Washington and was Ambassador to Afghanistan. He was Dean of the Fletcher School of Law and Diplomacy from 1978 to 1985 and a director of Raytheon Co. from 1983 to 1998. He is currently a director of Fiberstars, Inc. and of several non-profit organizations. Mr. Eliot holds B.A. and M.P.A. degrees from Harvard University.
| Organization | Position | Status |
|---|---|---|
| Neurobiological Technologies, Inc. | Board of Directors | Current |
William Fletcher was President & CEO of Teva?s North American activities from 1985 until the end of 2004, when he became Chairman ? North America. Teva, one of Israel?s largest industrial companies, holds the leading position in the global generic drug industry and commands a significant presence in the specialty neurology market. Mr. Fletcher served as Vice President, Sales and Marketing of the Pennsylvania based Lemmon Company (1980 to 1983) and then as President (1983-1985) following the company?s acquisition by Teva and WR Grace. Prior to 1980, Mr. Fletcher was Business Development Manager and International Marketing Manager of Synthelabo, a pharmaceutical subsidiary of L?Oreal in Paris. From 1970 to 1977 he served in various international sales and marketing positions for Hoffman-LaRoche. Mr. Fletcher graduated in International Marketing from Woolwich Polytechnic, London (now Greenwich University) in 1969. He serves as a Board Member for several Teva subsidiary companies in North America and Europe, and is a Director of Sportwall International Inc., a growth company in the interactive fitness industry.
| Organization | Position | Status |
|---|---|---|
| Sportwall International, Inc. | Director | Current |
| Neurobiological Technologies, Inc. | Board of Directors | Current |
| W.R. Grace & Company | Former | |
| Greenwich University | Former |
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes

